The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd

BSE 531633 · NSE LINCOLN · ISIN INE405C01035 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹614.35

+0.19%

BSE close, 28 August 2026

Market cap

₹1,230.53 cr

2.0 cr shares · Micro cap

Free float

₹584.97 cr

as published

P/E · P/B

12.8× · 1.92×

EPS ₹48.16 · BV ₹319.97

FY25-26 rev / PAT

671.03 / 87.89

₹ cr, as filed

Filings, window

11

4 selected · 36%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹439.95 52-WK HIGH ₹770.00 ₹614.35 53% of range
Against 52-week high-20.2%
Against 52-week low+39.6%
Day change+0.19%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹48.16
Price / earnings12.76×
Price / book1.92×
Book value — derived, price ÷ P/B₹319.97
Return on equity15.09%
Operating margin29.16%
Net margin20.44%

Consistency check

P/B ÷ P/E, which must equal ROE
15.05%
ROE as published
15.09%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 177.28 36.24 18.09 29.16% 20.44%
Mar-26 · Q 187.28 11.64 5.81 11.03% 6.21%
FY25-26 671.03 87.89 43.88 19.54% 13.10%

Quarter on quarter

Revenue, quarter on quarter
-5.3%
Net profit, quarter on quarter
+211.3%
Operating margin, quarter on quarter
+1,813 bps

Disclosure profile 11 filings in the window

0 median 17.0 p75 · 25 sector max 52 11 22th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Change in Management2
Board Outcome1
Results1
Selected sub-total4
Procedural
Newspaper Publication3
AGM / EGM1
Board Meeting1
Compliance Certificate1
Trading Window1
Procedural sub-total7
Total11

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

11 filings · 4 selected · busiest 2026-08-13 and 2026-09-24

Filing rhythm · the twelve most recent

2026-08-062026-10-07

SelectedProcedural

Filings

11 in the window · 2 earlier on record

  1. 7 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate from RTA for the Quarter ended September 30, 2026 under Regulation 74(5) of SEBI (DP) Regulations, 2018.

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 30 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Submission of Proceedings of the 32nd Annual General Meeting of the Company held today.

    AGM/EGM / AGM View filing →

  3. 24 September 2026 ·

    Change in Management

    Change in Management

    We wish to informed you that Mr. Pradeep Kumar Yadav has been appointed as " Senior General Manager- Quality Assurance (Senior Management Personnel) of the Company w.e.f 24-09-2026.

    Company Update / Change in Management View filing →

  4. 24 September 2026 ·

    Change in Management

    Change in Management

    Change in Senior Management.

    Company Update / Change in Management View filing →

  5. 23 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation of Closure of Trading Window.

    Insider Trading / SAST / Closure of Trading Window View filing →

  6. 7 September 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication for Notice of 32nd Annual General Meeting.

    Company Update / Newspaper Publication View filing →

  7. 26 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Advertisement regarding the 32nd Annual General Meeting of the Company to be held on Wednesday, September 30, 2026.

    Company Update / Newspaper Publication View filing →

  8. 14 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June, 2026.

    Company Update / Newspaper Publication View filing →

  9. 13 August 2026 ·

    Results

    Un-Audited Financial Results For Quarter Ended On 30 June, 2026.

    Un-Audited Financial Results For Quarter Ended on 30 June, 2026.

    Result / Financial Results View filing →

  10. 13 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Board Meeting Outcome For Un-Audited Financial Results For The Quarter Ended On June 30, 2026.

    Un-Audited Financial Results of the Company For the Quarter Ended June 30, 2026.

    Board Meeting / Outcome of Board Meeting View filing →

  11. 6 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Board Meeting Intimation For Consideration And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Lincoln Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Lincoln Pharmaceuticals ....

    Board Meeting / Board Meeting View filing →

RSS feed for Lincoln Pharmaceuticals Ltd · the 50 most recent filings